Antibody Discovery Market Outlook from 2024 to 2034

Future Market Insights’ updated report estimates the global antibody discovery market size to grow by 2.6X over the next ten years- from US$ 8.5 billion in 2024 to US$ 21.8 billion by 2034. Global demand is anticipated to surge at 9.9% CAGR throughout the forecast period, indicating the growing importance of antibodies in modern medicine.

Phage display remains the most preferred method for antibody discovery globally, recording a CAGR of 9.7%. This can be attributed to its versatility, robustness, applicability, and other advantages.

Attributes Key Insights
Base Market Value (2023) US$ 7.6 billion
Market Size in 2024 US$ 8.5 billion
Market Revenue in 2034 US$ 21.8 billion
Value-based CAGR (2024 to 2034) 9.9%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Global Market Overview

Antibody therapeutics is transforming the field of medicine, offering a new ray of hope for patients with diseases that were considered untreatable previously. It has paved the way for the development of novel drug classes called therapeutic antibodies.

Growing popularity of therapeutic antibodies due to their specificity, potency, and versatility is set to boost market growth. These drugs are showing promising results in diseases like cancer and autoimmune diseases, which is fueling their demand.

Monoclonal antibodies, protein-based therapeutics, and other biologics offer several advantages over traditional small-molecule drugs. These include their greater specificity and minimal side effects. Growing interest in such biologics will create greater demand for antibody discovery technologies.

Widening application area of antibodies beyond therapeutics is another key factor boosting market growth. In the contemporary world, antibodies are being increasingly used in diagnostic applications like point-of-care testing and immunoassays. Similarly, their usage is increasing in research and biotechnology applications.

Ongoing advances in antibody technology are anticipated to result in the development of more effective treatments for several diseases. This will bode well for the market during the next ten years.

Companies are looking to develop next-generation antibody formats, including antibody-drug conjugates (ADCs), bispecific antibodies, and engineered antibodies with improved specificity and functionality. Similarly, novel technologies like AI and ML are being incorporated into discovery workflows. These factors will further boost growth of the target industry.

A Brief Glimpse of Historical Growth Vs. Future Projections Comparison

The global market recorded a robust CAGR of 12.4% during the historical period, with total market valuation reaching US$ 7.6 billion in 2023. In the next ten years, a CAGR of 9.9% is on the cards for the target industry, depicting a deduction of 2.5% CAGR from the historical period. By 2034, the global antibody discovery market valuation is set to reach US$ 21.8 billion.

Historical CAGR (2019 to 2023) 12.4%
Forecast CAGR (2024 to 2034) 9.9%

Historically, demand for global demand grew rapidly. This was mostly due to thriving biopharmaceutical industry and increased popularity of biologics, particularly during the COVID-19 pandemic.

Increased collaboration between some leading players and academic institutions also positively impacted the market. Similarly, a shift towards patient-centric drug development, coupled with increased demand for personalized medicine, boosted the market.

The future of antibody discovery market looks bright owing to rising cases of chronic diseases and escalating demand for novel therapies. Ongoing advances in antibody technologies will also play a key role in facilitating market growth.

Investigating new therapeutic areas such as pediatrics, neurology, and rare diseases is anticipated to uplift demand for antibody discovery through 2034. Increasing government support and favorable regulatory frameworks for developing and approving biologics like antibodies will also benefit the industry.

Advances in phage display, gene editing, and humanization techniques are facilitating the discovery process. They allow for the development of more specific and potent antibodies, which will directly impact market growth in coming years.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Prominent Factors Propelling Antibody Discovery Market Growth

Growing Prevalence of Chronic and Infectious Diseases

One of the prominent factors influencing growth of the global market is the increasing incidence of chronic diseases like diabetes, cancer, and autoimmune diseases. These diseases often require novel treatments like antibodies.

Antibody-based therapies are becoming ideal tools for managing these chronic diseases due to their high effectiveness. They specifically bind to disease-causing molecules, thereby minimizing the risk of side effects. This, in turn, will create a high demand for antibody discovery services during the assessment period.

Rising Outsourcing Trends and High Investments in Research and Development

Leading biotechnology and pharmaceutical companies are rigorously investing in research and development to produce new antibody-based diagnostics and therapeutics. This is leading to the development of new technologies and platforms for antibody discovery.

Several pharmaceutical companies are also outsourcing their antibody discovery activities to prominent contract research organizations (CROs) to reduce costs and enhance their productivity. This will create lucrative growth opportunities for the target market.

Risks and Challenges in Antibody Discovery Market

There is no doubt that the antibody discovery industry has a bright future, especially in new therapeutics and diagnostics. However, it also faces certain challenges that might impact its growth.

One key challenge is the complex process of developing antibodies requiring substantial time and resources. Similarly, strict guidelines for antibody-based therapies and fierce competition are making it difficult for companies to survive in this industry.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Overview of Adjacent Markets

The section comprehensively evaluates three interrelated markets: the global antibody discovery industry, the antibody purification service market, and the drug discovery service industry. It dissects each market's distinctive characteristics, encompassing their respective CAGRs, while delving into the pivotal factors influencing their growth trajectories.

Global Antibody Discovery Market Forecast:

Attribute Global Market Analysis
CAGR (2024 to 2034) 9.9%
Growth Factor Escalating demand for targeted therapies like antibody-based drugs is set to boost market growth.
Antibody Discovery Market Trends Key growth-shaping trends include rising interest in personalized medicine and advances in biotechnology and immunology.

Global Antibody Purification Service Market Forecast:

Attribute Global Antibody Purification Service Industry Outlook
CAGR (2024 to 2034) 11.0%
Growth Factor Escalating demand for high-quality antibodies is anticipated to boost growth of the antibody purification service market.
Key Trends Growing adoption of antibody-based therapeutics will benefit the market.

Global Drug Discovery Service Market Analysis:

Attribute Global Drug Discovery Service Demand Outlook
CAGR (2024 to 2034) 14.5%
Growth Factor Escalating need for novel drugs to tackle diseases like cancer and rare genetic disorders is set to propel demand for drug discovery services.
Key Trends A key growth influencing trend is the integration of novel technologies like AI, ML, and data analytics in drug discovery.

Country-wise Insights

The table below shows the predicted growth rates of the key countries. South Korea, Japan, and the United Kingdom are set to record high CAGRs of 12.0%, 11.4%, and 11.1%, respectively, through 2034.

Countries CAGR (2024 to 2034)
United States 10.2%
United Kingdom 11.1%
China 10.7%
Japan 11.4%
South Korea 12.0%

The table below highlights key countries’ market revenues. The United States and China are forecast to remain leading markets, with predicted valuations of US$ 3.9 billion and US$ 3.4 billion, respectively, in 2034.

Countries Market Revenue (2034)
United States US$ 3.9 billion
United Kingdom US$ 880.5 million
China US$ 3.4 billion
Japan US$ 2.4 billion
South Korea US$ 1.4 billion

Escalating Demand for Targeted Therapies Boosting the United States Market

The United States market is anticipated to grow at a robust CAGR of 10.2% during the forecast period, with total valuation reaching US$ 3.9 billion by 2034. This can be attributed to rising cases of cancer and burgeoning demand for targeted therapies.

There has been a spike in cancer prevalence in the United States during the last few years, and the trend is set to escalate further in the coming years. According to the Centers for Disease Control and Prevention (CDC), the total number of cancer cases in the United States is estimated to increase by 49%, reaching 2,286,300 annual cases in 2050.

The high prevalence of cancer and other chronic diseases, in turn, is set to create a greater demand for therapeutic antibodies, thereby boosting market growth. Antibody-based therapies are becoming ideal solutions for attacking specific disease cells while leaving healthy cells unhealthy.

The United States is also home to several leading biopharmaceutical companies that are rigorously investing in antibody discovery research. This will have a positive impact on the United States market share and performance throughout the forecast period.

High Chronic Diseases Burden Propelling Demand in China

Future Market Insight’s latest analysis estimates China's industry value to total US$ 3.4 billion by 2034. Demand in the country will probably surge at a CAGR of 10.7% throughout the forecast period.

Multiple factors are stimulating growth of China market. These include high burden of chronic diseases, increasing government initiatives and funding programs, and ongoing advances in antibody development technologies.

Amid changing lifestyles and growing geriatric population, there is a serious increase in chronic diseases like cancer and cardiovascular diseases in China. To counter this, antibody-based therapies are becoming promising treatment solutions, resulting in higher demand in the country.

Category-wise Insights

The section below provides deeper insights into top segments and their respective values & shares in the global market. This information can help companies act accordingly and strengthen their presence in lucrative regions.

Based on method, the phage display segment is set to grow at 9.7% CAGR through 2034. By antibody type, the human antibody category will thrive at a CAGR of 9.5% from 2024 to 2034.

Phage Display Remains the Most Popular Method for Antibody Discover

Top Segment Phage Display (Method)
CAGR (2024 to 2034) 9.7%

Phage display continues to remain the most preferred method owing to its versatility, robustness, and other advantages. The target segment accounted for a prominent market share of 47.0% in 2023 and is set to thrive at 9.7% CAGR through 2034.

Phage display has become a powerful tool for antibody discovery as it allows rapid screening of millions of antibodies. It is ideal for the creation of vast antibody libraries, allowing researchers to look for specific antibodies with optimal therapeutic characteristics.

Researchers are widely using the phage display method as it helps them to yield high-affinity antibodies ideal for diverse uses. These antibodies find applications in diagnostics, therapeutics, and research tools.

The ability of phage display technology to discover antibodies against complex targets is another key factor encouraging its adoption. Thus, it will continue to remain a key tool in modern antibody therapeutics during the assessment period.

Multiple Benefits of Human Antibodies Giving them a Slight Edge

Top Segment Human Antibody (Antibody Type)
CAGR (2024 to 2034) 9.5%

As per the latest analysis, the human antibody segment will retain its dominance in the global market through 2034, recording a CAGR of 9.5%. This can be attributed to high adoption of human antibodies in several applications due to their numerous advantages.

Human antibodies display enhanced safety profiles, enhanced efficacy, and reduced immunogenicity. As a result, their application area is widening, ranging from combating cancer and autoimmune disorders to their diagnostic applications.

Human antibodies’ compatibility with human targets improves therapeutic effectiveness while reducing the risk of adverse immune reactions. They align with the rising demand for personalized medicine.

Most regulatory bodies favor human antibodies due to their excellent safety profiles. Growing popularity of drugs developed using human antibodies will further boost growth of the target segment during the assessment period.

Competitive Landscape

Several opportunities exist for companies amid burgeoning demand for antibodies for treating a wide range of diseases. To capitalize on this, top antibody discovery specialists are focusing on using advanced methods like hybridoma technology to create vast libraries of novel antibodies. Subsequently, they employ next-generation sequencing to analyze these libraries and identify promising candidates for specific biomarkers.

Automation is penetrating its roots in antibody production and purification processes, with companies looking to improve their throughput and efficiency. Top players are also adopting strategies like partnerships, collaborations, acquisitions, partnerships, and agreements to stay ahead of the curve.

Key Players in Antibody Discovery Market

  • Eurofins Scientific
  • Evotec
  • Twist Bioscience
  • Genscript Technology Corporation
  • Biocytogen
  • Sartorius AG
  • Danaher Corporation
  • Fairjourney Biologics S.A
  • Creative Biolabs
  • Charles River Laboratories

Recent Developments:

  • In October 2023, Tarrytown-based Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. joined hands in order to develop CRISPR-based gene editing therapies for the treatment of neurological and muscular diseases.
  • In September 2022, United Kingdom-based Abzena, a prominent CDMO providing integrated discovery and manufacturing of biologics and antibody drug conjugates (ADCs), upgraded its research and development capabilities in Cambridge to support rapid development of antibody therapeutics.
  • In June 2023, California-based AbTherx, Inc. introduced Atlas Mice, its next-generation human antibody discovery platform, to meet the growing demand for antibodies.
  • In April 2023, California-based Bio-Rad Laboratories, Inc. stepped into the future of therapeutics antibody therapeutics with the introduction of a new antibody discovery service specifically designed to develop best-in-class biologic candidates.
  • In February 2024, United States-based SCIEX introduced the Echo MS+system at SLAS 2024. It is designed to address key challenges in high throughput screening applications for drug discovery.

Key Coverage in Global Cell Therapy Growth Factor Market Research Report

  • Adjacent Study on Global Antibody Therapeutics Market, Research Antibodies Market, Plasma Fractionation Market, and Antibody Drug Conjugate Market
  • Investment Opportunities in Antibody Discovery Industry
  • Value Chain Analysis of Antibody Discovery Market
  • PESTLE and Porter’s Analysis of Antibody Discovery Market
  • Investment Feasibility Matrix Analysis of Antibody Discovery Market
  • Supply-side Trends of Antibody Discovery Market
  • Demand-side Trends of Antibody Discovery Industry
  • Geographics Growth Opportunities for Antibody Discovery Market
  • Recent Antibody Discovery Market Mergers and Acquisitions

Global Market Segmentation

By Method:

  • Phage Display
  • Hybridoma
  • Others

By Antibody Type:

  • Humanized Antibody
  • Human Antibody
  • Chimeric Antibody
  • Murine Antibody

By End-user:

  • Pharmaceutical and Biotechnology Industry
  • Research Laboratory
  • Academic Laboratory

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Middle East & Africa

Frequently Asked Questions

How big is the antibody discovery market?

The global market is set to be valued at US$ 8.5 billion in 2024.

What is the demand outlook for the market?

Global demand is forecast to grow at a CAGR of 9.9% through 2034.

What is the projected market size in 2034?

By 2034, the global market size is set to reach US$ 21.8 billion.

What was the historical CAGR of the industry?

The target industry registered a CAGR of 12.4% from 2019 to 2023.

What is the demand outlook for the United States market?

The United States is predicted to record a CAGR of 10.2% through 2034.

How big is the antibody market?

FMI estimates the global antibody market value to total US$ 581.42 billion by 2034.

What is the market for antibody therapy?

The antibody therapy market size is set to reach US$ 824.0 billion by 2033.

What is antibody discovery?

It is the process of identifying new antibodies that can bind to specific target molecules like proteins.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034

    4.1. Historical Market Size Value (US$ billion) Analysis, 2019 to 2023

    4.2. Current and Future Market Size Value (US$ billion) Projections, 2024 to 2034

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Methods

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ billion) Analysis By Methods, 2019 to 2023

    5.3. Current and Future Market Size Value (US$ billion) Analysis and Forecast By Methods, 2024 to 2034

        5.3.1. Phage Display

        5.3.2. Hybridoma

        5.3.3. Others

    5.4. Y-o-Y Growth Trend Analysis By Methods, 2019 to 2023

    5.5. Absolute $ Opportunity Analysis By Methods, 2024 to 2034

6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Antibody Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ billion) Analysis By Antibody Type, 2019 to 2023

    6.3. Current and Future Market Size Value (US$ billion) Analysis and Forecast By Antibody Type, 2024 to 2034

        6.3.1. Humanized Antibody

        6.3.2. Human Antibody

        6.3.3. Chimeric Antibody

        6.3.4. Murine Antibody

    6.4. Y-o-Y Growth Trend Analysis By Antibody Type, 2019 to 2023

    6.5. Absolute $ Opportunity Analysis By Antibody Type, 2024 to 2034

7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End Users

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ billion) Analysis By End User, 2019 to 2023

    7.3. Current and Future Market Size Value (US$ billion) Analysis and Forecast By End User, 2024 to 2034

        7.3.1. Pharmaceutical and Biotechnology Industry

        7.3.2. Research Laboratory

        7.3.3. Academic Laboratory

    7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023

    7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034

8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ billion) Analysis By Region, 2019 to 2023

    8.3. Current Market Size Value (US$ billion) Analysis and Forecast By Region, 2024 to 2034

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Western Europe

        8.3.4. Eastern Europe

        8.3.5. South Asia and Pacific

        8.3.6. East Asia

        8.3.7. Middle East and Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    9.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023

    9.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034

        9.2.1. By Country

            9.2.1.1. United States

            9.2.1.2. Canada

        9.2.2. By Methods

        9.2.3. By Antibody Type

        9.2.4. By End Users

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Methods

        9.3.3. By Antibody Type

        9.3.4. By End Users

    9.4. Key Takeaways

10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    10.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023

    10.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Methods

        10.2.3. By Antibody Type

        10.2.4. By End Users

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Methods

        10.3.3. By Antibody Type

        10.3.4. By End Users

    10.4. Key Takeaways

11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    11.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023

    11.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Western Europe

        11.2.2. By Methods

        11.2.3. By Antibody Type

        11.2.4. By End Users

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Methods

        11.3.3. By Antibody Type

        11.3.4. By End Users

    11.4. Key Takeaways

12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    12.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023

    12.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034

        12.2.1. By Country

            12.2.1.1. Poland

            12.2.1.2. Russia

            12.2.1.3. Czech Republic

            12.2.1.4. Romania

            12.2.1.5. Rest of Eastern Europe

        12.2.2. By Methods

        12.2.3. By Antibody Type

        12.2.4. By End Users

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Methods

        12.3.3. By Antibody Type

        12.3.4. By End Users

    12.4. Key Takeaways

13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    13.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023

    13.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034

        13.2.1. By Country

            13.2.1.1. India

            13.2.1.2. Bangladesh

            13.2.1.3. Australia

            13.2.1.4. New Zealand

            13.2.1.5. Rest of South Asia and Pacific

        13.2.2. By Methods

        13.2.3. By Antibody Type

        13.2.4. By End Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Methods

        13.3.3. By Antibody Type

        13.3.4. By End Users

    13.4. Key Takeaways

14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    14.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023

    14.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034

        14.2.1. By Country

            14.2.1.1. China

            14.2.1.2. Japan

            14.2.1.3. South Korea

        14.2.2. By Methods

        14.2.3. By Antibody Type

        14.2.4. By End Users

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Methods

        14.3.3. By Antibody Type

        14.3.4. By End Users

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country

    15.1. Historical Market Size Value (US$ billion) Trend Analysis By Market Taxonomy, 2019 to 2023

    15.2. Market Size Value (US$ billion) Forecast By Market Taxonomy, 2024 to 2034

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of Middle East & Africa

        15.2.2. By Methods

        15.2.3. By Antibody Type

        15.2.4. By End Users

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Methods

        15.3.3. By Antibody Type

        15.3.4. By End Users

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. United States

        16.1.1. Market Share Analysis, 2024

            16.1.1.1. By Methods

            16.1.1.2. By Antibody Type

            16.1.1.3. By End Users

    16.2. Canada

        16.2.1. Market Share Analysis, 2024

            16.2.1.1. By Methods

            16.2.1.2. By Antibody Type

            16.2.1.3. By End Users

    16.3. Brazil

        16.3.1. Market Share Analysis, 2024

            16.3.1.1. By Methods

            16.3.1.2. By Antibody Type

            16.3.1.3. By End Users

    16.4. Mexico

        16.4.1. Market Share Analysis, 2024

            16.4.1.1. By Methods

            16.4.1.2. By Antibody Type

            16.4.1.3. By End Users

    16.5. Germany

        16.5.1. Market Share Analysis, 2024

            16.5.1.1. By Methods

            16.5.1.2. By Antibody Type

            16.5.1.3. By End Users

    16.6. United Kingdom

        16.6.1. Market Share Analysis, 2024

            16.6.1.1. By Methods

            16.6.1.2. By Antibody Type

            16.6.1.3. By End Users

    16.7. France

        16.7.1. Market Share Analysis, 2024

            16.7.1.1. By Methods

            16.7.1.2. By Antibody Type

            16.7.1.3. By End Users

    16.8. Spain

        16.8.1. Market Share Analysis, 2024

            16.8.1.1. By Methods

            16.8.1.2. By Antibody Type

            16.8.1.3. By End Users

    16.9. Italy

        16.9.1. Market Share Analysis, 2024

            16.9.1.1. By Methods

            16.9.1.2. By Antibody Type

            16.9.1.3. By End Users

    16.10. Poland

        16.10.1. Market Share Analysis, 2024

            16.10.1.1. By Methods

            16.10.1.2. By Antibody Type

            16.10.1.3. By End Users

    16.11. Russia

        16.11.1. Market Share Analysis, 2024

            16.11.1.1. By Methods

            16.11.1.2. By Antibody Type

            16.11.1.3. By End Users

    16.12. Czech Republic

        16.12.1. Market Share Analysis, 2024

            16.12.1.1. By Methods

            16.12.1.2. By Antibody Type

            16.12.1.3. By End Users

    16.13. Romania

        16.13.1. Market Share Analysis, 2024

            16.13.1.1. By Methods

            16.13.1.2. By Antibody Type

            16.13.1.3. By End Users

    16.14. India

        16.14.1. Market Share Analysis, 2024

            16.14.1.1. By Methods

            16.14.1.2. By Antibody Type

            16.14.1.3. By End Users

    16.15. Bangladesh

        16.15.1. Market Share Analysis, 2024

            16.15.1.1. By Methods

            16.15.1.2. By Antibody Type

            16.15.1.3. By End Users

    16.16. Australia

        16.16.1. Market Share Analysis, 2024

            16.16.1.1. By Methods

            16.16.1.2. By Antibody Type

            16.16.1.3. By End Users

    16.17. New Zealand

        16.17.1. Market Share Analysis, 2024

            16.17.1.1. By Methods

            16.17.1.2. By Antibody Type

            16.17.1.3. By End Users

    16.18. China

        16.18.1. Market Share Analysis, 2024

            16.18.1.1. By Methods

            16.18.1.2. By Antibody Type

            16.18.1.3. By End Users

    16.19. Japan

        16.19.1. Market Share Analysis, 2024

            16.19.1.1. By Methods

            16.19.1.2. By Antibody Type

            16.19.1.3. By End Users

    16.20. South Korea

        16.20.1. Market Share Analysis, 2024

            16.20.1.1. By Methods

            16.20.1.2. By Antibody Type

            16.20.1.3. By End Users

    16.21. GCC Countries

        16.21.1. Market Share Analysis, 2024

            16.21.1.1. By Methods

            16.21.1.2. By Antibody Type

            16.21.1.3. By End Users

    16.22. South Africa

        16.22.1. Market Share Analysis, 2024

            16.22.1.1. By Methods

            16.22.1.2. By Antibody Type

            16.22.1.3. By End Users

    16.23. Israel

        16.23.1. Market Share Analysis, 2024

            16.23.1.1. By Methods

            16.23.1.2. By Antibody Type

            16.23.1.3. By End Users

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Methods

        17.3.3. By Antibody Type

        17.3.4. By End Users

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Danaher Corporation

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Eurofins Scientific

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Evotec

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Twist Bioscience

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Charles River Laboratories

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Genscript Technology Corporation

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Biocytogen

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Sartorius AG

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Fairjourney Biologics S.A

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Creative Biolabs

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Antibody Market

July 2021

REP-GB-1330

March 2024

333 pages

Healthcare

Drug Discovery Services Market

February 2022

REP-GB-14258

April 2023

306 pages

Healthcare

Drug Discovery Outsourcing Market

April 2023

REP-GB-16937

324 pages

Healthcare

Antibody Purification Service Market

September 2024

REP-GB-12088

Upcoming

Explore Healthcare Insights

View Reports
Future Market Insights

Antibody Discovery Market